Sandoz Phases US Epinephrine Entry
Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.
You may also be interested in...
Sandoz is encouraging US doctors to write prescriptions for epinephrine that include its Symjepi pre-filled syringes, and not just for auto-injector devices, as it targets the retail sector.
As it continues to shape its US portfolio towards more complex dosage forms, comprising biosimilars, value-added medicines and complex generics, Sandoz has announced its third launch of 2019 in the world’s largest market.
A differentiated offering that includes biosimilars, value-added medicines and digital health technologies is central to Sandoz’ mission to improve both patient health and its own profit margins, according to CEO Richard Francis.